Guest post on AACR 2013 by Philippe Aftimos, MD a medical oncologist at Institut Jules Bordet in Brussels with his reflections on new developments in cancer biomarkers and clinical trial design.
Update on new techniques for identifying and overcoming resistance in advanced lung cancer
Meghna Das Thakur from Novartis shows that treating with BRAF inhibitor with intermittent dosing lead to improved survival for metastatic melanoma
There were around 6,000 posters and many oral sessions at this year's AACR meeting in Washington DC, but what new trends emerged this year?
Bromodomain inhibition is a novel cancer target and one that I am looking forward to learning more about at forthcoming annual meeting of the American Association for Cancer Research (AACR) in Washington DC.
